Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non-Current Liabilities: 2021

Historic Other Non-Current Liabilities for ARS Pharmaceuticals (SPRY) over the last 1 years, with Dec 2021 value amounting to $83,000.

  • ARS Pharmaceuticals' Other Non-Current Liabilities was N/A to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year change of. This contributed to the annual value of $83,000 for FY2021, which is N/A change from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Other Non-Current Liabilities of $83,000 as of FY2021.
  • In the past 5 years, ARS Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $83,000 in FY2021 and a low of $83,000 during FY2021.
  • For the 1-year period, ARS Pharmaceuticals' Other Non-Current Liabilities averaged around $83,000, with its median value being $83,000 (2021).